Eli Lilly is expanding its Indiana insulin manufacturing operations, marking the first expansion of the company's Indianapolis sites in more than twenty years. The company will provide more details Thursday, but noted in a statement that the new capacity is to meet US demand. The site will make insulin cartridges.
Novartis continues to focus on making Singapore its biotech and manufacturing hub. The company announced Wednesday that it was investing more than $500 million in building a manufacturing facility that will focus on drugs based on cell culture technology. The company said in a statement it expects work to wrap by 2016, and the site will be able to scale up or down to handle a variety of production volumes.